Track topics on Twitter Track topics that are important to you
Phone: 49 9221 82762-0
Fax: 49 9221 82762-99
The first medicine that uses RNA interference, a method cells employ to mute a gene before it can make a harmful protein, has made its way to Europe. Three weeks after the FDA approved patisiran (Onpa...
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
[Updated at 3:25 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon. The FDA has just approved Alnylam’s patisiran (Onpattro), making it the first medicine specifically cleared to...
Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA interfer...
Regulators OK'd the first RNA interference therapy in Europe, but a new report finds the list price between 967% and 1,821% above value thresholds.
The five-year deal will help support Alnylam's planned market launch of its RNAi therapeutic patisiran.
Alnylam Pharmaceuticals' Onpattro, or patisiran, was approved by the European Commission as a treatment for adult patients wi -More-
Approval of Alnylam’s RNAi therapy Onpattro starts a showdown in hATTR amyloidosis, where Alnylam’s legwork on a novel payment model could give it the edge.
Nizatidine Capsules USP Rx only
MANICURE by OPI FINISHING BUTTER
Retavase Reteplase, recombinant
Farming was first introduced to Europe in the mid-seventh millennium bc, and was associated with migrants from Anatolia who settled in the southeast before spreading throughout Europe. Here, to unders...
Yellow fever (YF) is an emerging expanding fatal arboviral disease that has been imported at least six times in Europe during the first half of 2018, while only seven travel-associated YF cases have b...
In the past decade, a large influx of migrants presented in Europe. Their country of origin was mainly either Syria or Eritrea. Public health institutions in host countries in Europe are challenged to...
Of ∼10.2 million people with chronic HCV infection in Europe, most are living in Eastern Europe (6.7 million) followed by Western Europe (2.3 million) and Central Europe (1.2 million). HCV transmiss...
This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.
This is a multi-country, multicentre, observational cross-sectional one-visit study of patients with severe asthma in primary and secondary care settings in Europe
This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-month...
The investigators want to identify and show differences in standards and procedures of in-hospital rapid sequence induction by collecting data with an online survey for anaesthetist in Eur...
This is a prospective, non-interventional study (NIS) measuring health-related quality of life (HRQoL), treatment satisfaction, and other patient-reported outcomes (PROs) of ADPKD patients...
Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a ...
Europe Unlimited profiles and connects the community of Europe’s best tech entrepreneurs and international capital through research, networking events and consulting. As such, we are in a position t...
We have published hundreds of Alnylam Europe AG news stories on BioPortfolio along with dozens of Alnylam Europe AG Clinical Trials and PubMed Articles about Alnylam Europe AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Europe AG Companies in our database. You can also find out about relevant Alnylam Europe AG Drugs and Medications on this site too.
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...